Odiparcil

Cat. No.: HY-10277

CAS No.: 137215-12-4

Molecular Formula: $C_{15}H_{16}O_6S$

Molecular Weight: 324.35

Target: Thrombin

Pathway: Metabolic Enzyme/Protease

Storage:

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (308.31 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	3.0831 mL	15.4154 mL	30.8309 mL
5 mM	0.6166 mL	3.0831 mL	6.1662 mL
10 mM	0.3083 mL	1.5415 mL	3.0831 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events. Odiparcil (SB-424323) is indirect thrombin inhibitor that exerts its anticoagulant effect through activation of antithrombin II (heparin cofactor II) [1][2].

IC_{50} & Target

Thrombin[2]

REFERENCES

[1]. Myers AL, et al. Characterization of total plasma glycosaminoglycan levels in healthy volunteers following oral administration of a novel antithrombotic odiparcil with aspirin or enoxaparin. J Clin Pharmacol. 2008 Oct;48(10):1158-70

[2]. Levy JH, et al. Novel oral anticoagulants: implications in the perioperative setting. Anesthesiology. 2010 Sep;113(3):726-45.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA